Results 11 to 20 of about 9,498 (160)

Delivering Effective Hepatitis C Virus Treatment in an Embedded Primary Care Setting Within a Tertiary Care Hospital in Karachi, Pakistan. [PDF]

J Viral Hepat
ABSTRACT Hepatitis C virus (HCV) endemic regions require accessible treatment interventions. Effectiveness and costs of a pilot HCV treatment programme were evaluated at an embedded primary care service within a tertiary care centre at Indus Hospital and Health Network in Karachi, Pakistan.
Shah S, Mafirakureva N, Trickey A, Hasnain A, Khan U, Khowaja S, Ashraf H, Baig-Ansari N, Hickman M, Vickerman P, Walker JG, Lim AG.   +11 more
europepmc   +2 more sources

The outcome of the sofosbuvir Based Therapy in the treatment of Hepatitis C Virus Genotype 4 in Egyptian patients [PDF]

African Journal of Gastroenterology and Hepatology, 2019
Background and aim There have been significant advancements during the last few years, with large numbers of ongoing trials with various direct-acting antivirals (DAA) showing high potency against the hepatitis C virus (HCV).
Waleed Ismail, Amr Hanafy, Mohammed Abdelsattar   +2 more
doaj   +1 more source

Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa

BMC Health Services Research, 2022
Background Although direct-acting antivirals (DAA) have become standard care for patients with chronic hepatitis C worldwide, there is no evidence for their value for money in sub-Saharan Africa.
Sylvie Boyer, Maël Baudoin, Marie Libérée Nishimwe, Melina Santos, Maud Lemoine, Gwenaëlle Maradan, Babacar Sylla, Charles Kouanfack, Patrizia Carrieri, Abbas Mourad, Nicolas Rouveau, Raoul Moh, Moussa Seydi, Alain Attia, Maame Esi Woode, Karine Lacombe   +15 more
doaj   +1 more source

Novel combined single dose anti-hepatitis C therapy: a pilot study

Scientific Reports, 2021
The new anti-hepatitis C virus (HCV) molecules improve treatment regimens and outcomes, but there are drawbacks. New combinations should target the HCV infectious cycle and be effective against all HCV genotypes.
Gamal Shiha, Reham Soliman, Mohamed Elbasiony, Noureldien H. E. Darwish, Shaker A. Mousa   +4 more
doaj   +1 more source

Recurrent hyperkalemia in patients with chronic kidney disease and hepatitis C treated with direct antiviral agents

BMC Infectious Diseases, 2019
Background Sofosbuvir is the keystone of direct antiviral agents for the chronic hepatitis C (CHC). The safety of sofosbuvir in patients with stage 4–5 chronic kidney disease (CKD) needs further observation in real world.
Taotao Yan, Jiuping Wang, Juan Li, Shan Fu, Yi Chen, Chunhua Hu, Rou Zhang, Zhen Tian, Fahui Zhao, Jun Dong, Jinfeng Liu, Yuan Yang, Tianyan Chen, Yingren Zhao, Yingli He   +14 more
doaj   +1 more source

Medicament testing on acupuncture points as a non-invasive diagnostic tool for determining the daily doses of sofosbuvir in patients with chronic hepatitis C virus infection

Future Journal of Pharmaceutical Sciences, 2023
Background Acupuncture points are known for their unique bioelectric properties. Medication testing at acupuncture points has not previously been used to determine the daily doses of sofosbuvir in patients with chronic hepatitis C virus infection ...
Naylya Djumaeva, Gulnara Akhundjanova, Leyla Djumaeva, Dilbar Urunova   +3 more
doaj   +1 more source

Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. [PDF]

PLoS ONE, 2018
Thailand is encountering challenges to introduce the high-cost sofosbuvir for chronic hepatitis C treatment as part of the Universal Health Care's benefit package.
Waranya Rattanavipapong, Thunyarat Anothaisintawee, Yot Teerawattananon   +2 more
doaj   +1 more source

Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea [PDF]

Clinical and Molecular Hepatology, 2015
Background/AimsThe previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions.
Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim   +5 more
doaj   +1 more source

Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients

Journal of Transplantation, 2018
Background. Since the introduction of direct antiviral agents (DAAs), morbidity of HCV has considerably decreased but still no guidelines have been formulated in renal transplant recipients (RTRs). We studied efficacy and tolerability of direct antiviral
Sourabh Sharma, Debabrata Mukherjee, Ranjith K. Nair, Bhaskar Datt, Ananth Rao   +4 more
doaj   +1 more source

The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals.

PLoS ONE, 2021
BackgroundDirect-acting antiviral (DAA) drugs have been effective in the treatment of chronic hepatitis C virus (HCV) infection. Limited data are available on safety, tolerability, and efficacy in American Indian or Alaska Native people.
Lisa Townshend-Bulson, Elena Roik, Youssef Barbour, Dana J T Bruden, Chriss E Homan, Hannah G F Espera, Timothy J Stevenson, Annette M Hewitt, Wileina Rhodes, James E Gove, Julia N Plotnik, Mary M Snowball, John McGilvray, Brenna C Simons, Janet M Johnston, Brian J McMahon   +15 more
doaj   +1 more source